"Toward the end of 2021 TrialSite reported to the world that a nasal spray exhibited the ability to kill 99.9% of the SARS-CoV-2 virus. Called the SaNOTize Nitric Oxide Nasal Spray (NONS), this investigational product was designed to kill COVID-19 in the upper airways, in effect inhibiting the virus from incubating and thereby making its way to the host’s lungs. Developed by Vancouver-based SaNOtize Research and Development Corp, the product was helped along by testing done at the Utah State University Antiviral Research Institute. By the summer of 2021 the investigational product was evidencing positive results in Phase 2 clinical trials. By the end of 2021 various nations in the Middle East were embracing the drug from Bahrain to Israel. Now one of India’s largest generic drug producers, Glenmark Pharmaceuticals, embraced the nasal spray for distribution in the world’s second most populated nation. Just days ago, India’s regulatory, the Drug Controller General of India (DCGI) granted market authorization to Glenmark Pharmaceuticals– so now the product is authorized as a medical device targeting COVID-19 in India, Israel, Bahrain, Indonesia and Thailand. TrialSite has asked the question why not in the United States? Why is there so little news in the mainstream media? Are major pharmaceutical companies monopolizing the mindshare for vaccines and expensive branded therapies?"
Excerpt:
"Toward the end of 2021 TrialSite reported to the world that a nasal spray exhibited the ability to kill 99.9% of the SARS-CoV-2 virus. Called the SaNOTize Nitric Oxide Nasal Spray (NONS), this investigational product was designed to kill COVID-19 in the upper airways, in effect inhibiting the virus from incubating and thereby making its way to the host’s lungs. Developed by Vancouver-based SaNOtize Research and Development Corp, the product was helped along by testing done at the Utah State University Antiviral Research Institute. By the summer of 2021 the investigational product was evidencing positive results in Phase 2 clinical trials. By the end of 2021 various nations in the Middle East were embracing the drug from Bahrain to Israel. Now one of India’s largest generic drug producers, Glenmark Pharmaceuticals, embraced the nasal spray for distribution in the world’s second most populated nation. Just days ago, India’s regulatory, the Drug Controller General of India (DCGI) granted market authorization to Glenmark Pharmaceuticals– so now the product is authorized as a medical device targeting COVID-19 in India, Israel, Bahrain, Indonesia and Thailand. TrialSite has asked the question why not in the United States? Why is there so little news in the mainstream media? Are major pharmaceutical companies monopolizing the mindshare for vaccines and expensive branded therapies?"
Lugols iodine on a cotton bud is as good IMO, as is Xlear spray.